Introduction: Laparoscopic splenectomy (LS) is gaining acceptance as an effective and safe alternative to open splenectomy (OS) in the treatment of benign hematologic disorders unresponsive to medical treatment. Among these disorders, the most important is idiopathic thrombocytopenic purpura (ITP).
Patients And Method: We compared a cohort of 20 patients who had undergone LS in the previous 7 years, with a historical cohort of 38 patients who underwent OS between 1985 and 1999. All patients in the two groups were diagnosed with ITP unresponsive to medical treatment.
Results: The mean age of the patients was 41 years in the LS group and 39.7 in the OS group. Mean spleen size and weight were 11 cm and 150 g in the LS group and 9.9 cm and 190 g in the OS group. Preoperative platelet count was 78 x 10(9) in the LS group and 69 x 10(9) in the OS group. Accessory spleens were detected in 15% of patients in the LS group and in 16% of those in the OS group. The mean operative time was 180 minutes in LS and 85 minutes in OS (p < 0.001). The complications rate was 25% in LS and 21% in OS. The mean length of hospital stay was 3 days in the LS group and 9.4 days in the OS group (p < 0.001). No differences were observed in early and complete long-term remission.
Conclusions: Compared with OS, LS requires a longer operative time and reduces hospital stay. Detection of accessory spleens, complication rates, and effectiveness in terms of early and long-term remission are similar in both procedures. In our opinion, LS should be considered the procedure of choice for the treatment of benign hematological disorders unresponsive to medical therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0009-739x(07)71298-8 | DOI Listing |
Intensive Care Med
January 2025
Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, Paris, France.
Purpose: Advances in therapeutic care are leading to an increase in the number of patients living with overt immunosuppression. These patients are at risk of cytomegalovirus (CMV) infection and disease that can lead to or develop during ICU admission. This manuscript aims to describe the clinical presentation, risk factors, and management of CMV infection and disease in this patient population.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
GSK México, Torre Mitikah Piso 19 y 20, Circuito Interior Avenida Río Churubusco 601, Col. Xoco. Alc. Benito Juárez, Mexico City 03330, Mexico.
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here.
View Article and Find Full Text PDFVaccines (Basel)
November 2024
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy.
: HBV infections can lead to serious liver complications that can have fatal consequences. In 2022, around 1.1 million individuals died from HBV-related cirrhosis and hepatocellular carcinoma.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 80284, Taiwan.
Triple-negative breast cancer (TNBC) remains a significant therapeutic challenge due to its unresponsiveness to hormone and HER2-targeted treatments. This study investigated the potential of acetylated globotetraose (Ac-Gb4) as a novel therapeutic approach targeting glycolipid-mediated signaling in breast cancer cells. We synthesized acetylated globotetraose (Gb4) to enhance its membrane permeability while preserving its biological recognition properties.
View Article and Find Full Text PDFJ Clin Med
December 2024
Second Department of Internal Medicine, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Cardio-renal syndrome (CRS) is a complex condition involving bidirectional dysfunction of the heart and kidneys, in which the failure of one organ exacerbates failure in the other. Traditional pharmacologic treatments are often insufficient to manage the hemodynamic and neurohormonal abnormalities underlying CRS, especially in cases resistant to standard therapies. Device-based therapies have emerged as a promising adjunct or alternative approach, offering targeted intervention to relieve congestion, improve renal perfusion, and modulate hemodynamics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!